Stay updated on ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page's revision label changed from v3.5.3 to v3.5.4, indicating a new revision in the revision history. This update does not alter the content or behavior of the page.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page revision has been updated from v3.5.2 to v3.5.3, reflecting a new template release. It does not change the displayed study details or layout for users.SummaryDifference0.0%

- Check40 days agoChange DetectedRevision: v3.5.2 updated from v3.5.0. This appears to be a minor site update with no changes to study records.SummaryDifference0.0%

- Check69 days agoChange DetectedRevision indicator updated to v3.5.0. The previous revision v3.4.3 was removed.SummaryDifference0.0%

- Check76 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This indicates a software update rather than substantive content changes on the study page.SummaryDifference0.0%

- Check104 days agoChange DetectedAdded Revision: v3.4.2; removed the long funding-status notice and Revision: v3.4.1. The update does not affect the study details or how the page is used.SummaryDifference0.3%

Stay in the know with updates to ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.